Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Lung Cancer
•
Thoracic Malignancies
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
Non-small cell lung cancer
•
Ohio State University
•
NCI-CCC Thoracic Tumor Board Question
How would you treat oligometastatic NSCLC (brain and bone) with Non-V600E BRAF mutations?
SRS done to the single brain met, PD-L1 5%, BRAF G469A mutation
Answer from: Medical Oncologist at Academic Institution
I would treat with chemo-pembro. Down the road, MEK inhibitors is a choice.
Sign In
or
Register
to read more
8093
Related Questions
What are your top takeaways in Thoracic Cancers from ASCO 2025?
How would you manage a patient with non-mutated oligometastatic NSCLC with a brain met who underwent resection of the brain met, had 4 cycles chemoIO, and had resection of the primary lung CA with pCR and now is NED?
When will you select Dato-DXd for patients with EGFR-mutated non-small cell lung cancer?
Does anyone have experience obtaining sunvozertinib in the second-line setting for patients with EGFR exon 20 insertion mutations?
In NSCLC, would you manage other MET alterations, such as a MET T618T mutation, in the same way as a MET exon 14 skipping mutation?
Given potential long-term CV toxicity concerns with lorlatinib and data suggesting that dose reduction does not compromise efficacy, do you ever recommend initiating and/or maintaining lower-dose lorlatinib in ALK+ NSCLC?
How do you approach treatment selection among novel bispecific antibodies and ADCs for patients with EGFR+ NSCLC previously treated with 3rd generation EGFR inhibitors?
Would you give consolidation durvalumab to a patient who underwent chemoradiation for his stage III NSCLC and is being started on antifibrotic therapy by pulmonology for his ILD?
How do you approach treatment selection for patients with non-small cell lung cancer who have uncommon EGFR mutations compared to those with common mutations?
Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?